NT_1170x120_1-11-18

PCMA

PCMA makes statement on the administration’s Medicare Part D Rule

PCMA makes statement on the administration’s Medicare Part D Rule

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer J.C. Scott issued the following statement on the Administration’s final Medicare Part D rule: “We share the administration’s goal of reducing prescription drug costs in Medicare. We are pleased with the administration’s thoughtful approach to overseeing price concessions negotiated between pharmacies and PBMs that are

PCMA issues statement on prescription drug rebate legislation

PCMA issues statement on prescription drug rebate legislation

WASHINGTON — Pharmaceutical Care Management president and chief executive officer J.C. Scott issued the following statement on newly introduced legislation by Senator Mike Braun (R, Ind.), “The Drug Price Transparency Act:” “We stand ready to work with Senator Braun and other policymakers who share the goal of reducing high drug costs. Pharmacy benefit managers (PBMs) are the

PCMA’s Merritt issues statement on drug pricing

PCMA’s Merritt issues statement on drug pricing

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and chief executive officer Mark Merritt released the following statement on reports of yet another round of massive price hikes by drug manufacturers. “News of recent price increases by drugmakers further confirms that the easiest way to lower costs would be for drug companies to lower their prices.” This

PCMA applauds House passage of Bill curbing opioid epidemic

PCMA applauds House passage of Bill curbing opioid epidemic

WASHINGTON — Today, the U.S. House of Representatives passed a legislative package, SUPPORT for Patients and Communities Act (H.R. 6), which requires electronic prescribing (e-prescribing) of controlled substances in Medicare. “This is an important step in the fight against America’s opioid epidemic,” the Pharmaceutical Care Management Association (PCMA) said. E-prescribing of controlled substances ensures each prescription

PCMA president Mark Merritt to leave post in December

PCMA president Mark Merritt to leave post in December

WASHINGTON — After 15 years of heading up the Pharmaceutical Care Management Association (PCMA), chief executive officer and president Mark Merritt is stepping down, effective at year-end. Under Merritt’s leadership, PCMA grew from an obscure group into the nation’s leading voice on prescription drug benefits. One of his first missions was to help shape the bill

NACDS weighs in on burdens associated with DIR fees

ARLINGTON, Va. — The “untenable” procedures around direct and indirect remuneration fees (DIR fees) can be righted with measures reducing costs for beneficiaries and the government, while promoting a more quality-driven health care system, says the National Association of Chain Drug Stores. NACDS expressed that message in comments to the Centers for Medicare & Medicaid

NCPA, APA file brief in drug pricing case

NCPA, APA file brief in drug pricing case

ALEXANDRIA, Va. — The National Community Pharmacists Association and the Arkansas Pharmacists Association (APA) have filed an amici curiae brief in federal court against a challenge by the Pharmaceutical Care Management Association (PCMA). NCPA said the brief, filed in the U.S. Court of Appeals for the Eighth Circuit, supports Arkansas in a lawsuit initiated by

What’s the story with PBMs?

What’s the story with PBMs?

A lobbying event in Washington has triggered salvoes between two combatants: independent community pharmacies and pharmacy benefit managers. The National Community Pharmacists Association is holding its Congressional Pharmacy Fly-In advocacy drive this week, where it will also release “The PBM Story: What They Say, What They Do, and What Can Be Done About It,” offered

Senator: C-THRU bill ‘shines light’ on drug pricing

Senator: C-THRU bill ‘shines light’ on drug pricing

WASHINGTON — Sen. Ron Wyden (D., Ore.) has introduced the Creating Transparency to Have Drug Rebates Unlocked Act (C-THRU), aimed at bringing more visibility into prescription drug pricing by pharmacy benefit managers. The C-THRU legislation, initiated Wednesday in the Senate Finance Committee, would require PBMs serving Medicare Part D plans to disclose the aggregate rebates

Congressmen take aim at PBMs

Congressmen take aim at PBMs

A half-dozen congressmen pointed a finger at pharmacy benefit managers (PBMs) on the floor of the House of Representatives last week in an hour of comments on the high cost of prescriptions drugs, the National Community Pharmacists Association (NCPA) said in its Executive Update e-newsletter. In the session, Reps. Doug Collins (R., Ga.), Brian Babin

PCMA explains drug price transparency

PCMA explains drug price transparency

With high prescription drug costs a pillar of the national debate on health care, the Pharmaceutical Care Management Association (PCMA) is trying to shed some light on drug pricing. The Washington, D.C.-based PBM trade group on Wednesday released a video titled, “What is drug price transparency?”. PCMA said the goal is to show how transparency

N.Y. governor clamps down on drug pricing

N.Y. governor clamps down on drug pricing

(*Note: Go to 42:05 of video for Cuomo’s discussion of prescription drug costs.) ALBANY, N.Y. — New York Gov. Andrew Cuomo unveiled a three-pronged plan to check soaring prescription drug prices, which he called a “tremendous problem” for the state and its residents. In his 2017 State of the State address on Wednesday, Cuomo proposed